We are live on ! Find out more
FULC icon

Fulcrum Therapeutics

172 hedge funds and large institutions have $763M invested in Fulcrum Therapeutics in 2025 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 43 increasing their positions, 49 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

269% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 16

230% more call options, than puts

Call options by funds: $8.87M | Put options by funds: $2.69M

54% more capital invested

Capital invested by funds: $496M → $763M (+$267M)

33% more funds holding

Funds holding: 129172 (+43)

25.18% more ownership

Funds ownership: 99.44%124.62% (+25%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

12% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 49

Holders
172
Holders Change
+43
Holders Change %
+33.33%
% of All Funds
2.09%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
59
Increased
43
Reduced
49
Closed
16
Calls
$8.87M
Puts
$2.69M
Net Calls
+$6.18M
Net Calls Change
+$4.66M
Name Holding Trade Value Shares
Change
Change in
Stake
SCM
1
Suvretta Capital Management
New York
$74.2M +$12M +1,180,111 +22%
RCM
2
RA Capital Management
Massachusetts
$68.5M -$42.5M -4,175,139 -41%
TCM
3
TCG Crossover Management
California
$59.4M
NCM
4
Nantahala Capital Management
Connecticut
$48.6M -$3.84M -377,438 -8%
BlackRock
5
BlackRock
New York
$48.2M +$5.67M +557,011 +15%
Vanguard Group
6
Vanguard Group
Pennsylvania
$40.3M +$5.7M +560,088 +19%
B
7
Braidwell
Connecticut
$34.6M +$28.9M +2,841,734 +1,295%
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$27.1M +$24.4M +2,398,232 New
SL
9
Siren LLC
Connecticut
$22.1M +$19.8M +1,950,000 New
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$21.6M +$4.73M +464,332 +32%
FTM
11
First Turn Management
California
$21.4M +$19.3M +1,892,683 New
GP
12
GSK plc
$20.2M +$18.2M +1,785,714 New
Adage Capital Partners
13
Adage Capital Partners
Massachusetts
$19.2M -$7.45M -732,000 -30%
IC
14
Ikarian Capital
Texas
$15.6M +$878K +86,247 +7%
Aberdeen Group
15
Aberdeen Group
United Kingdom
$14.2M +$11.4M +1,116,066 +809%
ACM
16
ADAR1 Capital Management
Texas
$14.2M +$9.28M +912,137 +267%
Citadel Advisors
17
Citadel Advisors
Florida
$13.7M +$3.59M +352,448 +41%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$12.5M +$1.04M +101,762 +10%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$11.9M -$2.53M -248,184 -19%
State Street
20
State Street
Massachusetts
$11.4M -$589K -57,862 -5%
Balyasny Asset Management
21
Balyasny Asset Management
Illinois
$11M -$4.89M -480,041 -33%
VPC
22
Vestal Point Capital
New York
$10.7M +$9.67M +950,000 New
GPP
23
Great Point Partners
Connecticut
$9.05M +$8.14M +800,000 New
Acadian Asset Management
24
Acadian Asset Management
Massachusetts
$8.33M +$2M +196,099 +36%
Connor, Clark & Lunn Investment Management (CC&L)
25
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$6.59M +$2.02M +198,239 +52%

FULC Hedge Fund Activity: Q4 2025 in Review

172 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q4 2025, worth a combined $763M — up 54% from $496M a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new FULC positions and 16 closed out — a net gain of 43 holders — while 43 added to existing stakes and 49 trimmed.

The largest buyer was Braidwell, adding an estimated $28.9M. The largest seller was RA Capital Management, cutting an estimated $42.5M.

  • 172 institutional investors held Fulcrum Therapeutics (FULC) as of Q4 2025, up from 129 in Q3 2025.
  • Funds reported $763M of Fulcrum Therapeutics stock for Q4 2025, up 54% quarter-over-quarter.
  • 59 funds opened new Fulcrum Therapeutics positions in Q4 2025 and 16 closed out, a net change of +43 holders.
  • The largest Fulcrum Therapeutics buyer in Q4 2025 was Braidwell, an estimated $28.9M added.
  • The largest Fulcrum Therapeutics seller in Q4 2025 was RA Capital Management, an estimated $42.5M sold.

Based on aggregated 13F filings for Q4 2025.